Russell Investments Group Ltd. Buys 61,330 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Russell Investments Group Ltd. raised its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 30.0% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 265,777 shares of the company’s stock after purchasing an additional 61,330 shares during the period. Russell Investments Group Ltd.’s holdings in Teva Pharmaceutical Industries were worth $4,085,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Resona Asset Management Co. Ltd. grew its holdings in Teva Pharmaceutical Industries by 5.0% during the first quarter. Resona Asset Management Co. Ltd. now owns 342,223 shares of the company’s stock valued at $5,247,000 after purchasing an additional 16,302 shares during the period. Public Sector Pension Investment Board grew its holdings in Teva Pharmaceutical Industries by 7.0% during the first quarter. Public Sector Pension Investment Board now owns 587,167 shares of the company’s stock valued at $9,025,000 after purchasing an additional 38,400 shares during the period. Todd Asset Management LLC grew its holdings in Teva Pharmaceutical Industries by 11.0% during the first quarter. Todd Asset Management LLC now owns 2,932,742 shares of the company’s stock valued at $45,076,000 after purchasing an additional 290,154 shares during the period. Nuveen LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter valued at about $40,827,000. Finally, Virtu Financial LLC bought a new stake in Teva Pharmaceutical Industries during the first quarter valued at about $371,000. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Eric A. Hughes sold 52,742 shares of the company’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. Insiders have sold a total of 65,001 shares of company stock worth $996,958 over the last ninety days. Company insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $18.4660 on Friday. The stock has a 50 day moving average of $16.75 and a 200 day moving average of $16.28. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80. The firm has a market cap of $21.18 billion, a PE ratio of -115.41, a PEG ratio of 1.11 and a beta of 0.62. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. During the same period in the prior year, the company earned $0.61 earnings per share. The firm’s revenue was up .3% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TEVA. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price objective for the company. Hsbc Global Res raised Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. Finally, UBS Group dropped their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Buy” and an average target price of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.